Accuracy of In Vivo Multimodal Optical Imaging for Detection of Oral Neoplasia by Pierce, Mark C. et al.
2012;5:801-809. Published OnlineFirst May 2, 2012.Cancer Prev Res 
  
Mark C. Pierce, Richard A. Schwarz, Vijayashree S. Bhattar, et al. 
  
Oral Neoplasia
 Multimodal Optical Imaging for Detection ofIn VivoAccuracy of 
  
Updated version
  
 10.1158/1940-6207.CAPR-11-0555doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 1.html
http://cancerpreventionresearch.aacrjournals.org/content/suppl/2012/05/02/1940-6207.CAPR-11-0555.DC
Access the most recent supplemental material at:
  
  
  
Cited Articles
  
 http://cancerpreventionresearch.aacrjournals.org/content/5/6/801.full.html#ref-list-1
This article cites by 35 articles, 9 of which you can access for free at:
  
Citing articles
  
 http://cancerpreventionresearch.aacrjournals.org/content/5/6/801.full.html#related-urls
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.org
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
  
Permissions
  
.permissions@aacr.org
To request permission to re-use all or part of this article, contact the AACR Publications Department at
Research. 
on August 20, 2013. © 2012 American Association for Cancercancerpreventionresearch.aacrjournals.org Downloaded from 
Published OnlineFirst May 2, 2012; DOI: 10.1158/1940-6207.CAPR-11-0555 
Research Article
Accuracy of In VivoMultimodal Optical Imaging for Detection
of Oral Neoplasia
Mark C. Pierce1, Richard A. Schwarz1, Vijayashree S. Bhattar2, Sharon Mondrik1, Michelle D. Williams3,
J. Jack Lee4, Rebecca Richards-Kortum1, and Ann M. Gillenwater2
Abstract
If detected early, oral cancer is eminently curable. However, survival rates for oral cancer patients remain
low, largely due to late-stage diagnosis and subsequent difficulty of treatment. To improve clinicians’ ability
to detect early disease and to treat advanced cancers, we developed a multimodal optical imaging system
(MMIS) to evaluate tissue in situ, at macroscopic and microscopic scales. The MMIS was used to measure
100 anatomic sites in 30 patients, correctly classifying 98% of pathologically confirmed normal tissue sites,
and 95% of sites graded as moderate dysplasia, severe dysplasia, or cancer. When used alone, MMIS
classification accuracy was 35% for sites determined by pathology as mild dysplasia. However, MMIS
measurements correlated with expression of candidate molecular markers in 87% of sites with mild
dysplasia. These findings support the ability of noninvasive multimodal optical imaging to accurately
identify neoplastic tissue and premalignant lesions. This in turnmay have considerable impact on detection
and treatment of patients with oral cancer and other epithelial malignancies. Cancer Prev Res; 5(6); 801–9.
2012 AACR.
Introduction
Oral cancer is one of the 10 most common malignancies
worldwide, with incidence and mortality rates continuing
to rise (1). Despite easy accessibility of the mouth to
examination, most patients present with advanced tumors,
when treatment is more difficult, more expensive, and less
successful than early interventions (2). White light exam-
ination (WLE), the current approach to screening and
identification of oral cancer, has low sensitivity and spec-
ificity (3, 4). The same techniques are used to determine the
extent of lesions in the surgical setting, in which an excision
margin extending up to 1 cmbeyond the clinically apparent
tumorborder is recommended to achieve complete removal
of neoplastic tissue.
Wide-field autofluorescence imaging (AFI) has emerged
as a promising technique to improve the clinician’s ability
to detect and treat oral neoplasia (3, 5–7). AFI illuminates
several centimeters of tissue with UV or blue light, produc-
ing visible fluorescence from various tissue components,
predominantly stromal collagen. Tissue alterations associ-
ated with neoplastic development, such as of loss of colla-
gen integrity and epithelial thickening can lead to a decrease
in observed fluorescence intensity, whichmay be viewed by
eye or captured by a camera. In an ongoing study with a
commercially available AFI device termed the VELscope,
255 of 279 (91%) of sites with dysplasia, carcinoma in situ,
or invasive cancer were detected by loss of fluorescence
intensity (8). Significantly, over one-quarter of the sites in
the study had pathologic diagnoses of low-grade dysplasia,
supporting the potential for AFI to detect early-stage lesions
in addition to advanced disease.
AFI may also enable surgeons to better identify the
peripheral extent of neoplastic lesions during surgery. In a
study by Poh and colleagues, 19 of 20 tumors showed a loss
of fluorescence intensity extending 4 to 25 mm beyond the
clinically visible margin (9). A total of 32 of 36 tissue sites
within these regions of fluorescence loss showed dysplasia
or cancer on histopathology, suggesting that excision mar-
gins determined by conventional examination may under-
estimate the true extent of disease. Long-term data support
this hypothesis; a 2009 report fromPoh and colleagues (10)
presented outcomes on patients who underwent surgical
removal of oral lesions between 2004 and 2008, with
margins established either by conventional WLE, or by AFI.
A total of 25% of patients in the conventional examination
group (7 of 28) had recurrence of severe dysplasia or cancer,
whereas none of the 32 patients whosemargins were guided
by fluorescence imaging showed recurrence.
Although this loss of autofluorescence intensity seems to
be a sensitive indicator of dysplastic or neoplastic alteration
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(5, 11, 12), benign conditions including stromal inflam-
mation can mimic this effect on AFI, leading to reduced
specificity (13, 14). In a recent study of 64 patients at high
risk for oral cancer, the sensitivity of the VELscope relative to
histology was 100%, but specificity was only 80.8% (15). A
separate AFI study in 126 patients with lesions in the oral
cavity suspicious for premalignancy resulted in a sensitivity
of 84.1% and a specificity of only 15.3% (16). These
findings raise concern over the viability of AFI alone to be
used as a screening tool for oral dysplasia and cancer, given
the potential for large numbers of false positive diagnoses.
In contrast to the macroscopic view provided by wide-
field AFI, high-resolution imaging techniques such as con-
focal microscopy and microendoscopy enable clinicians to
visualize in vivo many of the same morphologic features
used by pathologists to identify dysplastic and neoplastic
epithelium. Topical contrast agents such as acetic acid and
proflavine solution enhance the appearance of cell nuclei,
allowing features such as nuclear crowding and pleomor-
phism, and nuclear-to-cytoplasm (N/C) ratio, to be qual-
itatively and quantitatively evaluated in real time (17–19).
By selectively evaluatingmorphologic alterationswithin the
epithelial layer, confounding effects including stromal
inflammation may be avoided. However, these high-reso-
lution imaging techniques only interrogate a very small area
of tissue and therefore suffer from the same limitation of
biopsies and histopathology, namely the potential to miss
occult disease due to sampling error.
Given the individual strengths and limitations of wide-
field and high-resolution optical imaging techniques, we
hypothesized that the combination of these methods in a
multimodal approach may enable detection of oral prema-
lignant lesions and cancers with both high sensitivity and
specificity. In this study, wide-field AFI and high-resolution
microendoscopy were carried out in patients undergoing
surgery for oral cancer or dysplasia. At each imaged site, a
head andneck surgeonprovided a clinical impressionbased
on conventional examination; quantitative image-derived
metrics were calculated for each modality, and a definitive
diagnosis was provided by pathologic assessment.
Materials and Methods
Study population
The study was approved by the Institutional Review
Boards of the University of Texas MD Anderson Cancer
Center and Rice University. A total of 30 patients (16 male
and 14 female) more than 18 years of age scheduled for
surgical resection of clinically visible oral lesions were
recruited to the study; all provided written informed con-
sent before participation. Six of the 30 patients had under-
gone previous surgery at or near the site(s) measured in this
study. The median age of the study group was 70 years
(range: 28–95).
Imaging systems
Wide-field autofluorescence and white-light reflectance
images of the oral mucosa were acquired with a simplified
version of the multispectral digital microscope system
reported by Roblyer and colleagues (ref. 20; for technical
specifications, see Supplementary Fig. S1A). The second
imaging platform used in this study was a high-resolution
microendoscope (HRME) system. Technical details on the
HRME design have been described previously (21) and are
reported in Supplementary Fig. S1B.
Contrast agents
Following wide-field AFI and before imaging with the
HRME, up to 1 mL of proflavine solution (0.01% w/v in
sterile PBS) was applied topically to the oral mucosa with a
cotton-tipped applicator. Proflavine is a fluorescent contrast
agent which predominantly stains cell nuclei. The optical
absorption peak is at a wavelength of 445 nm, with an
emission maximum at 515 nm (21). Proflavine is not yet
U.S. Food and Drug Administration (FDA) approved for
internal use in the oral cavity, but it has a long history of safe
clinical use as a topical antiseptic agent (22) and has also
been used as a fluorescent contrast agent in confocal endo-
microscopy trials (23). Proflavine is also a component of
Triple Dye, a topical antiseptic routinely used in umbilical
care in newborns (24). We carried out this study with
proflavine under IND status from the FDA; there were no
adverse reactions attributed to proflavine noted in any
subject participating in the clinical trial.
Study protocol
All subjects were imaged while under general anesthesia
in the operating room, immediately before surgery. The
surgeon (AMG) first identified regions of interest by stan-
dard WLE, consisting of clinically abnormal sites and one
normal appearing site. At this time, before any imaging was
carried out, each site was described and classified for risk of
neoplasia by the surgeon as either normal, abnormal low
risk, abnormal high risk, or cancer, according to the criteria
listed in Supplementary Table S1. The surgeon was not
blinded to the history of the patient when making this
assessment, and for the purposes of the study, this desig-
nation was termed the "clinical impression." Next, digital
autofluorescence and white light images of each site were
acquiredwith thewide-field imaging system, using dimmed
room lights to minimize the collection of ambient light.
Proflavine solution was then applied topically to each site
selected, followed by placement of the HRME fiber optic
probe onto the mucosal surface. HRME images were
recorded with the probe placed at each site, with an addi-
tional digital photograph taken showing the location of
probe placement for subsequent identification of image and
biopsy sites. A 4-mm punch biopsy instrument was used to
remove tissue at each imaged site, including the one site
which appeared normal by clinical impression. These "nor-
mal" sites were selected at locations contralateral to the
diseased tissue, whenever possible, to match anatomical
sites. Specimens were either sent for immediate processing
by frozen section, or placed in fixative for standard histo-
pathology processing, according to the clinical discretion of
the treating physician. The entire imaging portion of the
study was typically completed in 10 to 15 minutes.
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Pathology processing and review
Hematoxylin and eosin (H&E) stained sections from all
biopsy specimens were reviewed by the study pathologist
(MDW), blinded to the results of optical imaging and
categorized as either normal/benign, mild dysplasia, mod-
erate dysplasia, severe dysplasia, or cancer according to the
WHO grading system (25). The normal/benign category
contained any site without a diagnosis of dysplasia or
cancer, yielding a total of 45 sites, 20 of which exhibited
chronic inflammation (18 mild/moderate, 2 severe). Rec-
ognizing that the diagnosis of mild dysplasia by H&E alone
can be challenging andmay bemade easier by supplement-
ing with molecular markers, biopsies with an H&E diagno-
sis of normal or dysplasia (any grade) were additionally
evaluated with immunohistochemical staining for the
molecular markers Ki-67, p63, and PHH3. Our rationale
for selecting these particular markers for evaluation was
based upon studies reported in the literature, discussed
below. We recognize that Ki-67, p63, and PHH3 may not
represent the optimal panel of markers for oral dysplasia or
neoplasia, but in the absence of awidely acceptedmolecular
marker for oral cancer/dysplasia, we elected to proceedwith
these 3 candidate markers.
Ki-67 is an established marker for cellular proliferation
and is associated with recurrence following resection of oral
dysplasia (26). Torres-Rendon and colleagues showed
increased expression levels of Ki-67 inoral tissues diagnosed
from normal to dysplasia to cancer (27). Ki-67 expression
level alone was not significantly different between dysplas-
tic tissueswhichprogressed to cancer and those that did not.
However, values obtained by combining Ki-67 expression
with additional biomarkers (Mcm2 or geminin) were sta-
tistically different, suggesting a role for Ki-67 in predicting
progression. Montebugnoli and colleagues reported a pro-
spective study of 47 consecutive patients with oral squa-
mous cell carcinoma (OSCC), evaluating Ki-67 expression
in histologically normal tissue distant from the primary
tumor. Although patients with oral dysplasia were not part
of the study, Ki-67 expression alone was shown to be a
promising prognostic factor for the disease-free survival rate
in OSCC patients (28).
Overexpression of the tumor suppressor homolog p63
has been shown in oral squamous carcinomas (29) and
other sites. p63 was also evaluated as a marker of prognosis
by Lo Muzio and colleagues in a 2007 study involving 64
OSCC patients (30). Although no statistically significant
differences were found between p63 expression and age,
sex, or tumor stage, patients with p63 overexpression were
found to have a poorer survival rate at 72 months (31%
survival) than those with normal p63 levels (80%). p63 has
also been assessed as a biomarker for predicting oral cancer
risk in patients with leukoplakia (31). In a study of 152
patients with oral preneoplastic lesions, significantly more
patients with p63-positive lesions went on to develop oral
cancers. Moergel and colleagues evaluated p63 as a marker
for radiation resistance and overall survival in 33 OSCC
patients by determining p63 expression in biopsies before
surgery (32). All tumors showed increased p63 expression,
with increased resistance to radiation and lower survival for
those patients with elevated p63.
Phosphohistone-H3 (PHH3) is a core histone protein,
staining for which highlights mitotic figures (33). Taken
together, we believe there is good support for the selection
of these 3 biomarkers as candidate biomarkers for oral
dysplasia and cancer.
For more information on immunohistochemical pro-
cessing methods, see the Supplementary Information.
Immunohistochemically stained tissue sections from
each measurement site were evaluated by the study patho-
logist and assigned a discrete immunohistochemistry
(IHC) score for each of the 3 markers, according to the
criteria shown in Supplementary Table S2.
Data analysis
At each anatomical measurement site, quantitative opti-
cal information was extracted from images in the following
manner: The location of each biopsy site was identified in
the corresponding wide-field white-light image by the sur-
geon (AMG). The tissue autofluorescence level at this site
was then quantified by calculating the average ratio of red-
to-greenpixel intensitywithin a region approximately 4mm
in diameter, centered on the biopsy site. To account for
patient-to-patient variability in native tissue autofluores-
cence intensity, this ratio was normalized by the same
parameter measured at a clinically normal appearing site
(20). This metric is subsequently referred to as the "Nor-
malized R/G ratio."
HRME images of proflavine-stained tissue primarily
reveal cell nuclei as discrete bright dots on a dark back-
ground. To quantify parameters related to nuclear mor-
phology, image analysis software was written (Matlab
R2010b) to automatically identify nuclei in individual
HRME images. The area of each nucleus was calculated,
enabling the averageN/C area ratio to be calculated for each
image. This metric is subsequently referred to as the "N/C
ratio."
Results
A total of 100 independent sites were imaged and biop-
sied in 30 patients; the anatomical distribution is reported
in Supplementary Table S3. The clinical impression of the
surgeon and the independent diagnosis of the pathologist
are provided for each site in Supplementary Table S4. Of the
30 patients, 15 had a pathology diagnosis of cancer, 14 a
diagnosis of dysplasia, and 1 had no pathologic evidence of
dysplasia or cancer.
Figure 1 presents examples of WLE, wide-field AFI, and
HRME imaging alongside the corresponding histopathol-
ogy for 2 different sites on the tongue of a 57-year-old
patient. Figure 1A–D is a site on the anterior tongue; based
on conventional WLE (Fig. 1A), this site was considered
normal by clinical impression. The specific measurement
site is indicated by the location of the high-resolution fiber
optic probe, seen entering the image from 10 o’clock.When
viewed in AFImode (Fig. 1B), this site appears bright blue in
Multimodal Optical Imaging for Detection of Oral Neoplasia
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appearance, characteristic of normal oralmucosa. The high-
resolution image obtained with the probe placed at this site
is shown in Fig. 1C. The field-of-view is a 720-mm wide
en face view, corresponding to the diameter of the fiber optic
probe seen in Fig. 1A. Cell nuclei appear as discrete dots,
sparsely and evenly distributed throughout the field-of-
view, characteristic of normal epithelium and consistent
with the histologic diagnosis of "normal" (Fig. 1D). Figure
1E toH presents the leftmidtongue of the same patient. The
specific measurement site (indicated in Fig. 1E by the fiber
optic probe) was considered "abnormal, high risk" by
clinical impression. Under AFI, the measurement site
(arrow in Fig. 1F) and surrounding tissue exhibited low
autofluorescence intensity. With the HRME probe placed at
themeasurement site (Fig. 1G), nuclei appeared significant-
ly more crowded and less uniformly spaced than at the
"normal" site, consistent with the histologic diagnosis of
"severe dysplasia" at this site (Fig. 1H).
The 2 sites presented in Fig. 1 were instances in which
clinical impression, wide-field AFI, high-resolution imag-
ing, and pathology diagnosis were all in agreement. In
contrast, Fig. 2 presents a case involving the floor-of-mouth
in a 43-year-old male which appeared normal on clinical
examination under white light (Fig. 2A); however, AFI
indicated a dark region with distinct loss of intensity,
approximately 1 cm in diameter extending to the right of
the frenulum (Fig. 2B).High-resolution imagingwithin this
region revealed local variations in subcellular morphology,
ranging from discrete well-spaced nuclei at the anterior
aspect (Fig. 2C, site "1") to an irregular, crowded appear-
ance of nuclei at the base of the frenulum (Fig. 2D, site "2").
Histopathology sections from these 2 sites indicated normal
mucosa at site "1" (Fig. 2E) and moderate dysplasia at site
"2" (Fig. 2F), consistent with the nuclear morphology
observed in the HRME images. An additional case illustrat-
ing a false positive finding by clinical examination and
AFI which appeared normal by HRME and pathology is
presented in Supplementary Fig. S2.
For each of the 100 measured sites, loss of autofluores-
cence in AFI was quantified by the normalized red-to-green
intensity ratio; nuclear size and crowdingwere quantified in
HRME images by theN/C ratio, as described in theMethods
section. Figure 3 shows values for all 100measurement sites,
grouped into 3 pathology categories; open circles indicate a
A B C D
E F G H
Figure 1. Multimodal optical
imaging in the oral cavity. A–D, a
normal site on the anterior tongue.
E–H, a site diagnosed with severe
dysplasia on the left mid tongue in
the same patient. A and E, WLE;
B and F, AFI; C and G, high-
resolution microendoscopy; and D
and H, histopathology sections. In
(E), scar tissue is apparent, with the
smaller lesion alongside. In (B) and
(F), arrows indicate the location of
the microendoscope probe, as
seen in (A) and (E). Scale bars
represent 100 mm.
A B
C D
E F
Figure 2. Multimodal optical imaging at the ﬂoor-of-mouth. A, the entire
area appeared normal on clinical examination. B, AFI revealed a region
with distinct lossof ﬂuorescence intensity at thepatient's right side.Cand
D, HRME images with the probe placed at sites "1" and "2" in panel (B),
respectively. E and F, histopathology sections from sites "1" and "2"
respectively in panel (B). Scale bars represent 100 mm.
Pierce et al.
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diagnosis of normal/benign, gray triangles indicate mild
dysplasia, and closed circles represent diagnoses of moder-
ate dysplasia, severe dysplasia, or cancer. Figure 3A shows
the normalized red-to-green autofluorescence intensity
ratio at each site; areas with loss of blue-green fluorescence
correspond to higher ratio values. A threshold value of 1.38
correctly classified normal sites versus mild/moderate/
severe dysplasia or cancer with 87% sensitivity and 76%
specificity. Although 97% of sites with a diagnosis of mod-
erate dysplasia, severe dysplasia, or cancer were correctly
classified using this threshold, only 76%of normal sites and
65% of sites with mild dysplasia were correctly classified
(Table 1). Figure 3B shows theN/C ratio,measuredwith the
HRME at the same sites as Fig. 3A. Higher N/C ratios result
from enlarged or crowded nuclei; a threshold value of 0.142
correctly classified these measurement sites with 84% sen-
sitivity and 71% specificity. Using this threshold, 92% of
sites with a diagnosis of moderate dysplasia, severe dyspla-
sia, or cancer were correctly classified using this threshold,
but only 71% of normal sites and 65% of sites with mild
dysplasia were correctly classified. As shown in Fig. 3C,
when these AFI and HRME parameters are used together, a
single linear threshold correctly classified 98% of normal
sites and 95% of sites with moderate/severe dysplasia, or
cancer (Table 1). However, Fig. 3 also illustrates that sites
with a pathology diagnosis of mild dysplasia (gray trian-
gles) are the most difficult to classify correctly; using mul-
timodal imaging, only 35%of siteswithmilddysplasiawere
correctly classified as abnormal (Table 1). In Fig. 3C, only 2
of 9 mild dysplasia sites in patients with a cancerous lesion
elsewhere in the oral cavity were classified as abnormal by
optical imaging. This suggested thatwhena lesionwithmild
dysplasia is classified as abnormal by optical imaging, it is
an indication of the biology of that specific site, and not a
generalized property of patients with oral cancer.
Recent data suggested that in addition to the dysplastic
changes apparent in H&E sections under light microscopy,
molecular abnormalities may also indicate early precancer-
ous changes in oral lesions (8, 10). We hypothesized that
theremay be a correlation between parametersmeasured by
optical imaging and candidate biomarker expression levels.
Biopsy specimens from all sites with a pathology grade of
normal (n¼45) or dysplasia (mild,moderate, or severe;n¼
37) were stained for Ki-67, p63, and PHH3 markers by
IHC. Figure 4 shows representative histopathology sections
stained for Ki-67, p63, and PHH3 from 2 different mea-
surement sites, both of which were graded asmild dysplasia
by H&E (Fig. 4A and E). Images in the top row (Fig. 4A–D)
were from a site classified by optical measurements as
normal, whereas the bottom row (Fig. 4E–H) were from
Figure 3. Quantiﬁcation of AFI and HRME images. Symbols represent the diagnosis for each site according to pathology. A, normalized ratio of red-to-green
autoﬂuorescence intensity at each of the 100 sites measured in the study. B, N/C area ratio for the same 100 sites shown in (A). C, classiﬁcation of
measurement sites using both wide-ﬁeld autoﬂuorescence and high-resolution morphology. Dashed lines represent linear threshold values to discriminate
between normal sites, and those with mild/moderate/severe dysplasia or cancer.
Table 1. Percentage of sites accurately classiﬁed by optical imaging for each pathologic grade
Pathology grade
Mild dysplasia
Normal (%) Histopathology (%) IHC stratiﬁed (%) Mod. Dysplasia–Cancer (%)
AFI alone 76 65 67 97
HRME alone 71 65 73 92
AFI þ HRME (MMIS) 98 35 87 95
NOTE: Data are presented for sites with mild dysplasia by standard histopathology considered "abnormal," and also following
stratiﬁcation of those mild dysplasia sites by biomarker status (p63 considered "normal," p63þ considered abnormal).
Multimodal Optical Imaging for Detection of Oral Neoplasia
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a site classified as abnormal. In the site classified as normal
by optical measurement, Ki-67 and p63 expression was
confined to the lower portion of the epithelium (Fig. 4B
and C), whereas these markers extend to the upper portion
of the epithelium for the site classifiedoptically as abnormal
(Fig. 4F andG). PHH3 staining highlightsmitotically divid-
ing cells at the basal layer in Fig. 4D,which is consistentwith
normal tissue. PHH3-positive cells extending above the
basal layer are apparent in Fig. 4H, which is an abnormal
finding associated with dysplasia.
Tissue sections were evaluated according to the objective
criteria described in Supplementary Table S2,with themean
IHC scores for each pathology grade and each biomarker
shown in Fig. 5A. The expression level of each biomarker
(reflected in themean IHC score) exhibited an increase with
increasing grade of dysplasia. When the expression of p63
alone is compared with dysplasia grade by H&E, we found
that more than 75% of sites graded as moderate or severe
dysplasia exhibited high p63 expression (Fig. 5B, left
group). Interestingly, more than 80% of those sites graded
as mild dysplasia and classified as "abnormal" by optical
measurement also showed high p63 expression, whereas
only 10% of the mild dysplasia sites classified as "normal"
by optical measurement exhibited high p63. When the
fraction of sites with positive IHC for the complete panel
of Ki-67, p63, and PHH3 biomarkers was calculated, we
again noted that most sites with high-grade dysplasia and
mild dysplasia with abnormal classification by optics were
also IHC positive (Fig. 5B, right group).
Optical measurement values for the sites with mild dys-
plasia are shown in Fig. 5C, stratified by p63 expression
level. Five of 6 sites with high p63 expression were classified
as neoplastic based on the optical image parameters. Sim-
ilarly, 8 of 9 sites with low p63 expression had optical
measurements which grouped them with sites considered
normal by H&E. After stratifying the 15 sites diagnosed as
mild dysplasia by pathology according to p63 status (with
low p63 expression considered normal and high p63 con-
sidered abnormal along with moderate dysplasia, severe
dysplasia, and cancer), we determined the accuracy of
A B C D
E F G H
Figure 4. Histopathology sections
of tissue from 2 sites with a
diagnosis of mild dysplasia. A–D,
sections from a site which was
classiﬁed as "normal" by optical
measurement. E–H, sections from
a site classiﬁed as "abnormal" by
optical measurement. A and E,
H&E-stained sections used by the
study pathologist to classify each
site as mild dysplasia.
Immunostained sections from the
same sites with (B) Ki-67, graded
low, (C) p63, low (D) PHH3, low, (F)
Ki-67, moderate, (G) p63, high, (H)
PHH3, high. Scale bars represent
100 mm.
Figure 5. Analysis of immunohistochemical staining of sections from tissue sites with a pathology diagnosis of normal or dysplasia. A, mean IHC score (see
main text for details) versus pathology grade established by H&E staining, for each of the markers Ki-67, PHH3, and p63. Error bars represent SEs. B, the
fraction of tissue sites with a positive IHC score for either p63 alone, or for the complete panel of markers tested (see text for deﬁnition). Data are shown
separated by the pathology grade established by H&E staining. C, plot of wide-ﬁeld autoﬂuorescence and high-resolution N/C ratio values for sites with a
pathology diagnosis of mild dysplasia, stratiﬁed by p63 status. Note that only 15 of the original 17 measurement sites are displayed because of
immunohistochemical processing artifacts in 2 cases. The dashed line represents the linear threshold shown in Fig. 3C to discriminate between normal
sites, and those with mild/moderate/severe dysplasia or cancer.
Pierce et al.
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classification by each optical imaging system alone and in
combination (Table 1). When stratified by p63 status, the
combination of autofluorescence and high-resolution
imaging correctly classified 87% of sites with a histologic
diagnosis of mild dysplasia. When used alone, the multi-
modal imaging system (MMIS) classified all sites with 76%
sensitivity and 98% specificity. Following stratification of
mild dysplasia sites by biomarker status, MMIS classified
all 100 measured sites with 93% sensitivity and 96%
specificity.
Discussion
Oral cancer presents several unmet clinical challenges
which are also common to other organ sites. Better tools are
needed to improve screening for early-stage disease, to
establish clear surgical margins in patients undergoing
treatment, and to monitor high-risk and postsurgery
patients for development or recurrence of malignant
tumors. Macroscopic AFI with laboratory prototypes and
commercial devices has been evaluated in multiple studies
with varying patient populations (6, 7, 9) and has shown
excellent sensitivity for identifying abnormal tissue through
loss of observed autofluorescence intensity. However, there
is concern that the technique has poor specificity because of
confounding benign conditions, including inflammation
(14, 34). The consequences of poor diagnostic specificity in
a screening tool are serious, including subjecting many
patients to unnecessary procedures, which has the added
effect of creating alarm among patients and increasing
medical costs. Poor specificity in the surgical setting will
result in excessive removal of normal tissue beyond the
tumor margins, resulting in compromised functional and
cosmetic outcomes. The ideal tissue visualization system
will improve both sensitivity and specificity for identifica-
tion of precancerous lesions and cancer, above that which is
currently achieved byWLE. In addition, improvedmethods
are required to evaluate early-stage lesions, particularly
those with mild dysplasia; histopathology is currently a
poor predictor of risk for progression of these lesions to
higher grade disease (35). Therefore, the ability to nonin-
vasively distinguish low-grade sites with a high probability
of malignant transformation from those which will natu-
rally regress would truly represent a paradigm shift in
clinical cancer care (8).
In the study reported here, quantitative multimodal
optical imaging correctly classified 98% of pathologically
confirmed normal tissue sites and 95% of sites graded as
moderate dysplasia, severe dysplasia, or cancer. However,
only 6 of 17 (35%) sites with a pathology grade of mild
dysplasia were correctly classified by optical imaging. We
evaluated all 37 sites with a pathology diagnosis of
dysplasia, for biomarkers whose expression is likely to
be modulated during the development of oral neoplasia
(27–34). Consistent with these earlier studies, expression
levels of Ki-67, PHH3, and p63 were all found to increase
with pathologic grade of dysplasia. When the 17 sites with
a pathology grade of mild dysplasia were stratified by p63
expression into the pathology "normal" or "abnormal"
groups, we found that optical imaging correctly classified
the 100 measured sites with 93% sensitivity and 96%
specificity. Although these findings are encouraging, we
acknowledge that the candidate biomarkers used here are
not yet established prognostic indicators; long-term fol-
low-up of a large, independent cohort of patients is the
most rigorous way to establish the accuracy of these, or
any other molecular marker(s), in predicting the risk of
progression. However, other studies have also suggested
that the probability of neoplastic progression may be
measured by noninvasive optical imaging methods. Guil-
laud and colleagues showed that samples with an elevated
nuclear phenotypic score (NPS) were more than 10 times
more likely to progress than those without (36). This NPS
incorporated the maximum nuclear radius, a parameter
which is related to the N/C ratio used here. Poh and
colleagues found high-risk LOH profiles in 63% of sites
exhibiting loss of autofluorescence at resected tumor
margins (9). These observations collectively raise the
possibility that multimodal imaging may facilitate in vivo
detection of molecularly abnormal yet clinically normal
tissue, an exciting prospect for advancing translation of
molecular tumor classification tests from the laboratory
into actual clinical care.
This study has several important clinical implications.
First, the ability to improve detection of oral premalignant
lesions would have tremendous impact in the screening
setting, by identifying lesions at a stage in which less
morbid, less expensive, and completely curative treatment
can be administered. The ability to objectively discriminate
between abnormalities with different biomarker profiles
would further impact clinical decision making. Mild dys-
plasia is particularly challenging for clinicians because it can
appear transiently in reaction to inflammation, trauma, or
contact allergy, or it can represent the initial stage in the
transitionofnormalmucosa towardhigh-gradedysplasia or
cancer (37). For those tissue sites that remain under suspi-
cion and require a biopsy for definitive diagnosis or molec-
ular analysis, optical imaging methods can assist the phy-
sician in selecting the most relevant site from which to
obtain the tissue specimen. In the surgical setting, delinea-
tion of the dysplastic or neoplastic margins is of the utmost
importance, given our current understanding of field can-
cerization and the high rates of recurrence among head and
neck cancer patients. Multimodal optical imaging could be
used to provide real-time guidance on resection margins,
alone or in combination with frozen section pathology.
This study has several strengths, including the use of
independent biopsies with blinded pathology review to
provide the gold standard diagnosis at each site measured.
The investigation was carried out with a unique cohort of
patients with high probability of dysplasia or cancer, lead-
ing to a distribution of pathology diagnosis across the
spectrum from normal, through increasing grades of dys-
plasia, to cancer.
The ultimate objective for diagnostic adjuvants is to be
able to predict which patients with potentially malignant
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disorders are at high riskof progression and to identify those
with low risk who will not require aggressive surveillance.
Noninvasive multimodal optical imaging classified tissue
sites into normal and neoplastic categories with higher
sensitivity and specificity than expert clinical impression.
Whereas sites with mild dysplasia proved the most difficult
to classify by any method, stratification with the candidate
biomarker p63 increased the classification accuracy of
MMIS at these sites. Althoughmolecular abnormalities have
traditionally only been identified in resected tissue, the
prospect of using optical imaging for real-time, in vivo
delineation of molecularly damaged mucosa is particularly
exciting and warrants further study. This includes establish-
ing a consensus on the appropriate biomarker (or markers)
which reliably indicatemalignant potential and then testing
optical imaging measurements against these markers in
longitudinal studies. Significantly, these principles have
potential to be extended to the screening, diagnosis, and
treatment of dysplasia and neoplasia in other organs
beyond the oral cavity.
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